argenx SE (NASDAQ:ARGX) Given Consensus Rating of “Moderate Buy” by Analysts

argenx SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-three brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $630.42.

ARGX has been the subject of a number of research analyst reports. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Piper Sandler lifted their target price on argenx from $553.00 to $620.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Citigroup lifted their target price on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Raymond James reaffirmed a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a report on Thursday, October 10th. Finally, Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th.

argenx Trading Up 1.2 %

Shares of NASDAQ:ARGX opened at $614.59 on Thursday. The stock has a fifty day simple moving average of $560.78 and a two-hundred day simple moving average of $492.76. The stock has a market capitalization of $37.10 billion, a price-to-earnings ratio of -698.40 and a beta of 0.61. argenx has a 12-month low of $327.73 and a 12-month high of $620.28.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the company earned ($1.25) EPS. As a group, equities research analysts predict that argenx will post 2.2 EPS for the current year.

Institutional Trading of argenx

Several institutional investors have recently made changes to their positions in the business. J.Safra Asset Management Corp grew its holdings in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after buying an additional 62 shares in the last quarter. GAMMA Investing LLC grew its stake in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after acquiring an additional 40 shares in the last quarter. Cromwell Holdings LLC grew its stake in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in argenx during the second quarter valued at $76,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.